The production of blood cells and their precursors from human pluripotent stem cells
(hPSCs) in vitro has the potential to make a significant impact upon healthcare provision. We …

Transfusion of donor-derived platelets is commonly used for thrombocytopenia, which
results from a variety of clinical conditions and relies on a constant donor supply due to the …

Thrombopoietin (TPO) or MpI ligand is known to stimulate megakaryocyte (MK) proliferation
and differentiation. To identify the earliest human hematopoietic cells on which TPO acts, we …

Background: Megakaryocytic development is driven by the transcription factor Growth Factor
Independence 1B (GFI1B) and its interaction with the chromatin remodeler Lysine Specific …

In vitro cultured blood cells for transfusion purposes provide a safe alternative to donor
blood, particularly for patients who require recurrent transfusions, and can be used as …

Background: The platelet fibrinogen receptor, a heterodimer consisting of integrin subunits α
IIb and β 3, is required for platelet aggregation, spreading, and hemostasis. Platelet agonists …

Objectives Unlimited self renewal capacity and the ability to differentiate into any cell type
make human pluripotent stem cells (PSC) a potential source for the ex vivo manufacture of …

Currently, there are insufficient sources of platelets for clinical transfusion, and there are
risks of alloimmune reactions and transfusion-transmitted infections (TTI) after transfusion. In …

Because of a lack of platelet supply and a US Food and Drug Administration-approved
platelet growth factor, megakaryocytes have emerged as an effective substitute for …